Innovent Biologics, Inc. (01801.HK) Latest Company News

Oct 28, 2026, 23:34 UTC
Innovent Biologics, Inc. reported third-quarter 2026 product revenue of more than RMB 4.7 billion, up more than 40% year over year.
Source:
Oct 27, 2026, 06:22 UTC
Hong Kong stocks fell in afternoon trading, with the Hang Seng Index testing 23,000 points as HSBC shares dropped more than 6.75% to HK$132.6 after its results and weighed on the index by about 110 points; Xiaomi, Meituan, NetEase, Inc., BeiGene, Ltd. and Innovent Biologics, Inc. also declined.
Source:
- aastocks.com
Oct 26, 2026, 11:54 UTC
Takeda Pharmaceutical plans to seek Japanese approval in fiscal 2027 for the gastric-cancer drug candidate arcotatug tabatacan, co-developed with Innovent Biologics, Inc., after a late-stage trial in 464 patients in Japan and China found it extended survival in patients with advanced disease.
Source:
- nikkei.com
Oct 23, 2026, 10:30 UTC
Innovent Biologics, Inc. announced positive topline Phase 3 G-HOPE-001 results for arcotatug tavatecan, reporting improved overall survival and progression-free survival versus physician’s choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction cancer.
Source:
- prnewswire.com
Oct 22, 2026, 04:12 UTC
Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.
Source:
Oct 21, 2026, 01:38 UTC
Innovent Biologics, Inc. and BeiGene shares each rose more than 4% in early trading.
Source:
- aastocks.com
Oct 16, 2026, 01:52 UTC
Hong Kong stocks rose more than 300 points in early trading to 24,392.3, while the Hang Seng Tech Index gained as much as 2.24% to 4,152, with Alibaba and biotechnology shares among the gainers.
Source:
Oct 14, 2026, 08:12 UTC
Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.
Source:
- aastocks.com
Oct 8, 2026, 04:12 UTC
Hong Kong-listed shares showed mixed moves at the half-day close, with H&H International Holdings, JNBY Design Ltd. and Chervon Holdings Ltd. reaching record highs.
Source:
- aastocks.com
Oct 2, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.
Source:
Sep 29, 2026, 01:45 UTC
China's National Medical Products Administration approved a new indication for Innovent Biologics' Jaypirca (pirtobrutinib), allowing single-agent use across all lines of treatment for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in China.
Source:
- aastocks.com
Sep 28, 2026, 08:12 UTC
Innovent Biologics shares fell 3.6% to HK$96.15 on 28 September 2026.
Source:
- aastocks.com
Sep 28, 2026, 04:12 UTC
Hong Kong stocks closed the morning session higher, with the Hang Seng Index up 156 points at 24,666 and the Hang Seng Tech Index down 23 points at 4,288, while Central New Energy hit a record high and Hua Hong Semiconductor fell over 4%.
Source:
- aastocks.com
- aastocks.com
Sep 21, 2026, 05:00 UTC
Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.
Source:
- cnbc.com
Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:
- aastocks.com
Sep 21, 2026, 02:17 UTC
Hong Kong stocks fell early then rebounded on Monday, with the Hang Seng Index dropping 13.86 points to 24,736.92 before rising over 145 points to 24,896.43, while biotech and pharmaceutical shares gained and Alibaba rose 2% and Alibaba Health fell 5%.
Source:
- aastocks.com
- aastocks.com
Sep 7, 2026, 00:17 UTC
Innovent Biologics' Suzhou manufacturing base passed an on-site GMP inspection by the European Medicines Agency and obtained an EU GMP certificate.
Source:
- aastocks.com
Aug 27, 2026, 03:50 UTC
Innovent Biologics reported interim results for the period, with net profit up 50.2% year-on-year and adjusted net profit up 40.5% year-on-year, both significantly beating market expectations.
Source:
- aastocks.com
Aug 25, 2026, 10:20 UTC
Innovent Biologics announced its interim results for the six months ended June 2026, with net profit up 50.2% to RMB 1.253 billion.
Source:
Aug 21, 2026, 06:26 UTC
Innovent Biologics (Suzhou) and Suzhou state-owned capital, among others, established a venture capital partnership, Suzhou Xinhe Guoqing Phase II Venture Capital Partnership (Limited Partnership), with a capital contribution of 185 million yuan.
Source:
- finance.sina.cn
Aug 20, 2026, 23:59 UTC
Hacker group FulcrumSec leaked 1.2 terabytes of data stolen from Danish pharmaceutical company Novo Nordisk on the open internet on 12 August 2026, following an earlier sample leak on 17 July 2026.
Source:
- ing.dk
Aug 19, 2026, 04:52 UTC
Morgan Stanley downgraded Baidu's rating to 'Underweight' and cut its target price to $80, citing accelerating AI investment.
Source:
- aastocks.com
Aug 14, 2026, 05:54 UTC
Innovent Biologics, in partnership with Meituan's pharmacy service, launched a new 2mg single-vial formulation of Mazdutide at the 2026 West China Health Industry Conference in Boao, Hainan, exploring instant retail.
Source:
- finance.sina.cn
Aug 10, 2026, 01:55 UTC
Innovent Biologics and Daiichi Sankyo entered an exclusive agreement granting Innovent sole commercialization rights for Vanflyta (quizartinib) in China, with Daiichi Sankyo handling development, manufacturing, and supply.
Source:
Aug 6, 2026, 00:21 UTC
Innovent Biologics announced that the first subject has been dosed in the third pivotal registration clinical Phase III study of IBI363/TAK-928 combined with bevacizumab for the treatment of advanced colorectal cancer.
Source:
Aug 5, 2026, 00:50 UTC
Innovent Biologics reached a commercialization partnership with Eli Lilly for the drug Verzenio (abemaciclib) in China, strategically expanding into the breast cancer treatment field.
Source:
- aastocks.com
- aastocks.com
Aug 5, 2026, 00:06 UTC
Innovent Biologics announced that its product revenue for the first half of 2026 exceeded 8.2 billion RMB, up over 55% year-on-year, with second-quarter product revenue exceeding 4.3 billion RMB, up about 60% year-on-year.
Source:
Jul 14, 2026, 00:00 UTC
Spero Therapeutics signed a cross-exclusive territory license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. for CD40L-targeting compounds including SP001 (IBI355).
Source:
Jun 30, 2026, 04:00 UTC
Innovent Biologics and Eli Lilly entered into a distribution and promotion agreement for Verzenios (abemaciclib) in mainland China.
Source:
Jun 29, 2026, 05:20 UTC
Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.
Source:
- reuters.com

01801.HK

Innovent Biologics, Inc. reported third-quarter 2026 product revenue of more than RMB 4.7 billion, up more than 40% year over year.

Hong Kong stocks fell in afternoon trading, with the Hang Seng Index testing 23,000 points as HSBC shares dropped more than 6.75% to HK$132.6 after its results and weighed on the index by about 110 points; Xiaomi, Meituan, NetEase, Inc., BeiGene, Ltd. and Innovent Biologics, Inc. also declined.

Takeda Pharmaceutical plans to seek Japanese approval in fiscal 2027 for the gastric-cancer drug candidate arcotatug tabatacan, co-developed with Innovent Biologics, Inc., after a late-stage trial in 464 patients in Japan and China found it extended survival in patients with advanced disease.

Innovent Biologics, Inc. announced positive topline Phase 3 G-HOPE-001 results for arcotatug tavatecan, reporting improved overall survival and progression-free survival versus physician’s choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction cancer.

Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.

Innovent Biologics, Inc. and BeiGene shares each rose more than 4% in early trading.

Hong Kong stocks rose more than 300 points in early trading to 24,392.3, while the Hang Seng Tech Index gained as much as 2.24% to 4,152, with Alibaba and biotechnology shares among the gainers.

Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.

Hong Kong-listed shares showed mixed moves at the half-day close, with H&H International Holdings, JNBY Design Ltd. and Chervon Holdings Ltd. reaching record highs.

Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.

China's National Medical Products Administration approved a new indication for Innovent Biologics' Jaypirca (pirtobrutinib), allowing single-agent use across all lines of treatment for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in China.

Innovent Biologics shares fell 3.6% to HK$96.15 on 28 September 2026.

Hong Kong stocks closed the morning session higher, with the Hang Seng Index up 156 points at 24,666 and the Hang Seng Tech Index down 23 points at 4,288, while Central New Energy hit a record high and Hua Hong Semiconductor fell over 4%.

Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.

Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

Hong Kong stocks fell early then rebounded on Monday, with the Hang Seng Index dropping 13.86 points to 24,736.92 before rising over 145 points to 24,896.43, while biotech and pharmaceutical shares gained and Alibaba rose 2% and Alibaba Health fell 5%.

Innovent Biologics' Suzhou manufacturing base passed an on-site GMP inspection by the European Medicines Agency and obtained an EU GMP certificate.

Innovent Biologics reported interim results for the period, with net profit up 50.2% year-on-year and adjusted net profit up 40.5% year-on-year, both significantly beating market expectations.

Innovent Biologics announced its interim results for the six months ended June 2026, with net profit up 50.2% to RMB 1.253 billion.

Innovent Biologics (Suzhou) and Suzhou state-owned capital, among others, established a venture capital partnership, Suzhou Xinhe Guoqing Phase II Venture Capital Partnership (Limited Partnership), with a capital contribution of 185 million yuan.

Hacker group FulcrumSec leaked 1.2 terabytes of data stolen from Danish pharmaceutical company Novo Nordisk on the open internet on 12 August 2026, following an earlier sample leak on 17 July 2026.

Morgan Stanley downgraded Baidu's rating to 'Underweight' and cut its target price to $80, citing accelerating AI investment.

Innovent Biologics, in partnership with Meituan's pharmacy service, launched a new 2mg single-vial formulation of Mazdutide at the 2026 West China Health Industry Conference in Boao, Hainan, exploring instant retail.

Innovent Biologics and Daiichi Sankyo entered an exclusive agreement granting Innovent sole commercialization rights for Vanflyta (quizartinib) in China, with Daiichi Sankyo handling development, manufacturing, and supply.

Innovent Biologics announced that the first subject has been dosed in the third pivotal registration clinical Phase III study of IBI363/TAK-928 combined with bevacizumab for the treatment of advanced colorectal cancer.

Innovent Biologics reached a commercialization partnership with Eli Lilly for the drug Verzenio (abemaciclib) in China, strategically expanding into the breast cancer treatment field.

Innovent Biologics announced that its product revenue for the first half of 2026 exceeded 8.2 billion RMB, up over 55% year-on-year, with second-quarter product revenue exceeding 4.3 billion RMB, up about 60% year-on-year.

Spero Therapeutics signed a cross-exclusive territory license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. for CD40L-targeting compounds including SP001 (IBI355).

Innovent Biologics and Eli Lilly entered into a distribution and promotion agreement for Verzenios (abemaciclib) in mainland China.

Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.